REDMOND, Wash., March 18, 2026 (GLOBE NEWSWIRE) -- Pattern Computer®, Inc. (“Pattern” or “the Company”), the global leader in Pattern Discovery, today announced expanded global intellectual property protection for its investigational cancer therapy candidate, PCI020302, a preclinical-stage oncology asset.
The Company has been granted patents in the United States and Mexico covering the composition and method of use for PCI020302, a proprietary combination of existing small molecule drugs targeting triple-negative breast cancer (TNBC). In Europe, Pattern has secured broad protection with its TNBC-focused patent granted and in force across multiple jurisdictions, including 17 European Union countries as well as the United Kingdom and Switzerland. In Australia, the corresponding patent application has been accepted and is proceeding toward grant. Collectively, these patents extend protection for PCI020302 through 2040, strengthening exclusivity around a lead oncology asset and supporting future development and partnership opportunities.
PCI020302 was identified using the Company’s PatternDE™ (PDE) platform and has demonstrated activity in preclinical animal models in studies conducted by an independent global contract research organization (CRO). The therapy is designed as a multi-drug combination approach to address the complexity of TNBC biology.
Triple-negative breast cancer is an aggressive and difficult-to-treat form of breast cancer that lacks targeted therapies and disproportionately affects younger and underserved populations. PCI020302 represents a combination-based therapeutic strategy leveraging synergistic interactions between existing drugs identified through Pattern’s proprietary PDE platform.
PDE is designed to uncover deep, explainable patterns in complex biological data, enabling the discovery of novel therapeutic combinations with strong experimental validation.
“We are excited to expand our global patent footprint for PCI020302 across key international markets,” said Mark Anderson, Chair and CEO of Pattern. “These milestones reflect both the strength of our underlying technology and our commitment to developing impactful therapies for patients facing aggressive cancers like TNBC. Our growing IP portfolio supports our mission to translate breakthrough discoveries into real-world solutions.”
PCI020302 is part of Pattern’s broader oncology pipeline, all derived from its PDE platform. The Company continues to pursue partnerships and development pathways to bring these innovations closer to clinical application.
About Pattern
Pattern Computer, Inc. is a next-generation AI platform company which uses its Pattern Discovery Engine™ to solve the most important and intractable problems in business and medicine. These proprietary mathematical techniques in advanced AI can find complex patterns in very-high-order data that have eluded detection by much larger systems, including LLMs. As the Company applies its computational platform to the challenging fields of drug discovery and diagnostics, it is also making major Pattern Discoveries for partners in other sectors, including extended biotech, climate challenges and materials science, aerospace manufacturing quality control, veterinary medicine, air traffic operations, equity trading, AI regulatory compliance in the EU, and energy services. See www.patterncomputer.com.
CONTACT: Laura Guerrant-Oiye (808) 960-2642 – laura@patterncomputer.com
The foregoing contains statements about Pattern Computer’s future that are not statements of historical fact. These statements are “forward looking statements” for purposes of applicable securities laws and are based on current information and/or management’s good faith belief as to future events. The words “believe,” “expect,” “anticipate,” “project,” “should,” “could,” “will,” and similar expressions signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance. By their nature, forward-looking statements involve inherent risk and uncertainties, which change over time, and actual performance could differ materially from that anticipated by any forward-looking statements. Pattern Computer undertakes no obligation to update or revise any forward-looking statement.
Copyright © 2026 Pattern Computer Inc. All Rights Reserved. Pattern Computer, Inc., Pattern Discovery Engine, PatternBio, TrueXAI, and ProSpectral are trademarks of Pattern Computer Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.
